Overview

TegMine Therapeutics is a biotechnology company focused on developing antibody-based therapies targeting cancer-associated glycans and glycoproteins. Their proprietary TegMiner™ platform enables the discovery of unique tumor-specific glycan epitopes, facilitating the creation of highly selective cancer treatments.

Therapeutic areas

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Tegmine Therapeutics in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.

For suppliers

Is this Tegmine Therapeutics?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.